Dianthus reports Q3 net loss $36.8M; gMG Ph2 data positive, CIDP Ph3 interim accelerated to Q2'26

Dianthus Therapeutics, Inc. /DE/

2025-Q3 EPS reported -$2.68 revenue$1,752,000

Net loss of $36.8M ($0.97/share) vs $25.2M ($0.74/share) Q3'24; R&D $32.5M on higher clinical costs.
Phase 2 MaGic trial of claseprubart in gMG met endpoints with stat sig MG-ADL and QMG improvements at Week 13.
CIDP Phase 3 CAPTIVATE trial interim responder analysis accelerated to Q2'26 (from 2H'26) due to faster enrollment.
In-licensed DNTH212 (bifunctional BDCA2/BAFF-APRIL inhibitor) from Leads Biolabs; Ph1 healthy volunteer data expected 2H'26.
Adjusted cash ~$525M after $30M DNTH212 milestone payments; runway into 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.